logo
AnaptysBio_Logo

AnaptysBio and GSK-partnered immuno-oncology agents JEMPERLI (dostarlimab-gxly) and cobolimab ...

AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that GSK’s study PERLA, a head-to-head trial of JEMPERLI vs. Keytruda in patients with metastatic non-squamous non-small cell lung cancer, met its primary endpoint of objective response rate (ORR) of dostarlimab plus chemotherapy versus pembrolizumab plus chemotherapy as assessed by blinded independent central review per RECIST v1.1.

By AnaptysBio, Inc.
Published - Oct 05, 2022, 09:04 AM ET
Last Updated - Apr 22, 2024, 06:23 AM EDT
  • Positive headline results from PERLA, a head-to head Phase 2 trial of JEMPERLI vs. Keytruda in patients with metastatic non-squamous non-small cell lung cancer
  • COSTAR, a Phase 2 trial of JEMPERLI plus cobolimab, an anti-TIM-3 antagonist antibody licensed to TESARO, Inc. (GSK) as part of the same collaboration agreement as JEMPERLI, achieved pre-specified efficacy and safety criteria
  • Combination of JEMPERLI plus cobolimab to advance to Phase 3 for the treatment of advanced non-small cell lung cancer where AnaptysBio expects to receive a $5 million milestone from GSK during Q4 2022 on dosing of the first patient with cobolimab
    • Article Source
    Quick Links
    Categories
    Our Offices
    • 10kInfo, Inc.
      13555 SE 36th St
      Bellevue, WA 98006
    • 10kInfo Data Solutions, Pvt Ltd.
      Claywork Create
      11 km, Arakere Bannerghatta Rd, Omkar Nagar, Arekere,
      Bengaluru, Karnataka 560076
    4.2 12182024